SILK vs. CSII, LUNG, INO, AXNX, TNDM, NARI, IRTC, ICUI, IART, and NVCR
Should you be buying Silk Road Medical stock or one of its competitors? The main competitors of Silk Road Medical include Cardiovascular Systems (CSII), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), Axonics (AXNX), Tandem Diabetes Care (TNDM), Inari Medical (NARI), iRhythm Technologies (IRTC), ICU Medical (ICUI), Integra LifeSciences (IART), and NovoCure (NVCR). These companies are all part of the "surgical & medical instruments" industry.
Silk Road Medical (NASDAQ:SILK) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
Silk Road Medical has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Cardiovascular Systems has higher revenue and earnings than Silk Road Medical. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Silk Road Medical, indicating that it is currently the more affordable of the two stocks.
Cardiovascular Systems received 328 more outperform votes than Silk Road Medical when rated by MarketBeat users. Likewise, 62.02% of users gave Cardiovascular Systems an outperform vote while only 50.56% of users gave Silk Road Medical an outperform vote.
In the previous week, Silk Road Medical had 4 more articles in the media than Cardiovascular Systems. MarketBeat recorded 4 mentions for Silk Road Medical and 0 mentions for Cardiovascular Systems. Silk Road Medical's average media sentiment score of 1.05 beat Cardiovascular Systems' score of -0.11 indicating that Silk Road Medical is being referred to more favorably in the media.
Cardiovascular Systems has a net margin of -15.79% compared to Silk Road Medical's net margin of -29.02%. Cardiovascular Systems' return on equity of -15.39% beat Silk Road Medical's return on equity.
Silk Road Medical currently has a consensus price target of $20.10, indicating a potential downside of 3.50%. Given Silk Road Medical's higher possible upside, research analysts clearly believe Silk Road Medical is more favorable than Cardiovascular Systems.
86.6% of Cardiovascular Systems shares are owned by institutional investors. 3.9% of Silk Road Medical shares are owned by company insiders. Comparatively, 3.8% of Cardiovascular Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Cardiovascular Systems beats Silk Road Medical on 9 of the 17 factors compared between the two stocks.
Get Silk Road Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SILK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SILK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silk Road Medical Competitors List
Related Companies and Tools
